Scinai Immunotherapeutics (SCNI)
NASDAQ:SCNI
Want to see SCNI full AI Analyst Report?
SCNI Stock Chart & Stats
$0.78
-$0.11(-3.01%)
At close: 4:00 PM EST
$0.78
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$0.45 - $6.18
Previous CloseN/A
Volume8.73K
Average Volume (3M)101.31K
Market Cap
$1.97M
Enterprise Value$1.35M
Total Cash (Recent Filing)$989.00K
Total Debt (Recent Filing)$2.36M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding3,535,489
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue1.18
Enterprise Value/Gross Profit-0.80
Enterprise Value/Ebitda0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetLeverage reduction and restored positive equity materially improve financial flexibility versus prior years. Lower debt decreases interest and covenant risk, giving the company longer runway to fund R&D and CDMO integration without immediate refinancing pressure, a durable improvement for the next several quarters.
Expanded CDMO FootprintAcquiring Recipharm Israel expands Scinai’s manufacturing scope across proteins, small molecules, peptides, antibodies and oligonucleotides and links early-stage services to a global late-stage network. This end-to-end CDMO capability creates structural differentiation and recurring revenue potential beyond one-off R&D milestones.
Non-dilutive Grant For AutomationSecuring substantial non-dilutive funding to validate an automated aseptic fill-and-finish system strengthens manufacturing quality and throughput while minimizing cash outlay. Automation aligned with EU GMP Annex 1 reduces contamination risk and supports higher-margin, scalable CDMO operations over the medium term.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow signals the business consumes material cash to fund operations and development. Without sustained revenue scaling or further financing, cash burn will pressure liquidity and force dilution or curtailed investment, affecting runway and strategic optionality over coming quarters.
Negative Gross Profit & Large Operating LossesNegative gross profit indicates core operations do not yet cover direct costs, an unsustainable margin profile absent structural change. Substantial operating losses will continue to erode equity and require either margin improvement from CDMO scale or continued external capital, constraining long-term profitability prospects.
Acquired Subsidiary Financial RiskPro forma disclosures for the Recipharm Israel unit reveal significant balance sheet and going-concern issues. Integrating a loss-making subsidiary with working capital and equity deficits raises near-term financing needs and operational risk, complicating consolidation and potentially increasing capital requirements.
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $0.45 and its highest was $6.18 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $1.97M.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is May 28, 2026 which is in 18 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on May 07, 2026. The company reported -$0.604 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.604.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 3,535,489 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of -$0.604 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.737%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Technical Analysis
Ownership Overview
―
Insiders
0.42% Other Institutional Investors
99.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---